Raludotatug deruxtecan (R-DXd) received FDA breakthrough therapy designation for CDH6-expressing platinum-resistant ovarian, primary peritoneal, or fallopian tube cancers. Phase 1 study demonstrated a ...
Trastuzumab deruxtecan (T-DXd) significantly improves IDFS over trastuzumab emtansine (T-DM1) in high-risk HER2-positive early breast cancer post-neoadjuvant therapy. The DESTINY-Breast05 trial ...
The FDA has granted priority review to the supplemental biologics license application (sBLA) of fam-trastuzumab ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback